

# Charles E Phelps

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4565812/publications.pdf>

Version: 2024-02-01

44  
papers

2,072  
citations

430874

18  
h-index

276875

41  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1911  
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic foundations of cost-effectiveness analysis. <i>Journal of Health Economics</i> , 1997, 16, 1-31.	2.7	605
2	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. <i>Value in Health</i> , 2018, 21, 131-139.	0.3	321
3	On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses. <i>International Journal of Technology Assessment in Health Care</i> , 1991, 7, 12-21.	0.5	145
4	Focusing Technology Assessment Using Medical Decision Theory. <i>Medical Decision Making</i> , 1988, 8, 279-289.	2.4	138
5	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 2018, 21, 161-165.	0.3	113
6	Diffusion of Information in Medical Care. <i>Journal of Economic Perspectives</i> , 1992, 6, 23-42.	5.9	111
7	A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 154-162.	5.1	71
8	Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]. <i>Value in Health</i> , 2018, 21, 146-154.	0.3	59
9	Evaluating Frameworks That Provide Value Measures for Health Care Interventions. <i>Value in Health</i> , 2017, 20, 185-192.	0.3	44
10	Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. <i>Value in Health</i> , 2021, 24, 244-249.	0.3	43
11	Health technology assessment with risk aversion in health. <i>Journal of Health Economics</i> , 2020, 72, 102346.	2.7	41
12	Clinical Implications of Referral Bias in the Diagnostic Performance of Exercise Testing for Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2013, 2, e000505.	3.7	35
13	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562.	1.6	35
14	A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis. <i>Value in Health</i> , 2019, 22, 785-791.	0.3	32
15	How do health insurance loading fees vary by group size?: implications for Healthcare reform. <i>International Journal of Health Care Finance and Economics</i> , 2011, 11, 181-207.	1.2	31
16	Using Multicriteria Approaches to Assess the Value of Health Care. <i>Value in Health</i> , 2017, 20, 251-255.	0.3	28
17	Perspectives in health economics. <i>Health Economics (United Kingdom)</i> , 1995, 4, 335-353.	1.7	25
18	Good Technologies Gone Bad. <i>Medical Decision Making</i> , 1997, 17, 107-117.	2.4	23

#	ARTICLE	IF	CITATIONS
19	Optimal health insurance. <i>Journal of Risk and Insurance</i> , 2023, 90, 213-241.	1.6	16
20	Costs and Clinical Outcomes Associated with Use of Ranolazine for Treatment of Angina. <i>Clinical Therapeutics</i> , 2012, 34, 1395-1407.e4.	2.5	14
21	A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE). <i>European Journal of Health Economics</i> , 2022, 23, 433-451.	2.8	14
22	A priority-setting aid for new vaccine candidates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3199-3200.	7.1	13
23	Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. <i>Vaccine</i> , 2017, 35, A46-A49.	3.8	13
24	Bridging the gap: Need for a data repository to support vaccine prioritization efforts. <i>Vaccine</i> , 2015, 33, B34-B39.	3.8	12
25	Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 155-162.	2.1	12
26	Vision for a systems architecture to integrate and transform population health. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12595-12602.	7.1	9
27	Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease. <i>American Heart Journal</i> , 2014, 167, 697-706.e2.	2.7	8
28	Strategic Planning in Population Health and Public Health Practice: A Call to Action for Higher Education. <i>Milbank Quarterly</i> , 2016, 94, 109-125.	4.4	8
29	Compare voting systems to improve them. <i>Nature</i> , 2017, 541, 151-153.	27.8	7
30	Resource allocation in decision support frameworks. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 48.	1.5	7
31	Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist. <i>Medical Decision Making</i> , 2018, 38, 778-788.	2.4	6
32	When Opportunity Knocks, What Does It Say?. <i>Value in Health</i> , 2019, 22, 851-853.	0.3	6
33	Economic Issues of Breastfeeding. <i>Breastfeeding Medicine</i> , 2011, 6, 307-311.	1.7	5
34	Planning and priority setting for vaccine development and immunization. <i>Vaccine</i> , 2017, 35, A50-A56.	3.8	5
35	Estimating optimal willingness to pay thresholds for cost-effectiveness analysis: A generalized method. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1697-1702.	1.7	5
36	Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. <i>Sleep Medicine</i> , 2017, 38, 44-49.	1.6	4

#	ARTICLE	IF	CITATIONS
37	25 years of excellence: The Journal of Health Economics in retrospective. Journal of Health Economics, 2007, 26, 1075-1080.	2.7	3
38	Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. Patient, 2020, 13, 557-566.	2.7	2
39	Economics of Healthcare Financing: Implications for Breastfeeding. Breastfeeding Medicine, 2010, 5, 191-199.	1.7	1
40	Patents and drug insurance: Clash of the Titans?. Science Translational Medicine, 2018, 10, .	12.4	1
41	Valuing Health: Evolution, Revolution, Resistance, and Reform. Value in Health, 2019, 22, 505-510.	0.3	1
42	1067Multi-Attribute Ranking Tool for Vaccines: Strategic Priority Setting to Support Vaccine Development. Open Forum Infectious Diseases, 2014, 1, S313-S313.	0.9	0
43	Tackling Heterogeneity. Medical Decision Making, 2014, 34, 944-947.	2.4	0
44	Remembering a Giant in Economics: Kenneth J. Arrow (1922â€“2017). Value in Health, 2017, 20, 999.	0.3	0